News

At the 44th National Association of Pediatric Nurse Practitioners Conference, guidelines for prescribing oral contraceptives were discussed.

At the 44th National Association of Pediatric Nurse Practitioners Conference, evidence-based approaches for supporting pregnant adolescents were discussed.

Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN, pediatric nurse practitioner, discusses the vital role of nurse practitioners and key takeaways from the 44th National Association of Pediatric Nurse Practitioners Conference.

At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on the effectiveness of vaccines and antivirals in preventing life threatening conditions.

At the 44th National Association of Pediatric Nurse Practitioners Conference, the CDC provided an updated immunization schedule, detailing new changes.

At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with type 1 diabetes were at high risk for developing anorexia and bulimia.

At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on how to diagnose and treat polycystic ovarian syndrome in adolescent patients.

In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).

In a recent study, the Ask Suicide-Screening Questions (ASQ) and the Computerized Adaptive Screen for Suicidal Youth (CASSY) tools both showed predictive viability for suicide attempts in adolescents.

The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.

In a recent study, children aged 5 to 11 years were less likely to be hospitalized with the Omicron strand if they received vaccination against COVID-19.

In a recent study, penicillin allergy documentation was uninformative in allergy tabs, and children were not often referred to allergists.

Covis, the manufacturer of the controversial preterm birth prevention drug Makena, has announced it will voluntarily withdraw the drug from the market after recommendations from the Center for Drug Evaluation and Research.

In a recent study, the prevalence of e-cigarette use was greater among sexual minority youth than heterosexual or questioning youth.

In a recent study, a poor connection was reported between mental health emergency department discharge and follow-ups through outpatient care.

A supplemental New Drug Application for empagliflozin (Jardiance; Boehringer Ingelheim and Eli Lilly and Company) in pediatric patients with type 2 diabetes has been accepted by the FDA.

In a recent study, the risk of death from respiratory diseases during adulthood almost doubled in individuals who experienced a lower respiratory tract infection at a young age.

Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.

Children were hospitalized the most during the Omicron variant, but disease outcomes were the least severe during this variant period.

A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.

In a new policy statement, the American Academy of Pediatrics has provided guidelines on reducing crowding in emergency departments.

In a recent study, the rate of suicidal ideation was 1.7 times greater among adolescents with depression who had experienced a violent encounter in the past year.

Data from AAAAI 2023 suggests that gut microbial composition, function, and metabolic activity are implicated in the efficacy of peanut oral immunotherapy in children with peanut allergy.

In a recent study, worse neurodevelopmental outcomes were seen in children born preterm and with postnatal growth failure.

Velmanase alfa-tycv (Lamzede, Chiesi Global Rare Diseases) has received approval by the FDA for treating alpha-mannosidosis in adult and pediatric patients.

From AI-powered symptom checking to virtual intake tools, recent technological advances hold promise for enhancing care delivery.

Results of a recent review showed that adalimumab, etanercept, golimumab, and infliximab are effective and well-tolerated treatments options for patients with juvenile idiopathic arthritis.

Omaveloxolone (SKYCLARYS, Reata Pharmaceuticals) has received FDA approval for treating Friedreich’s ataxia in patients aged 16 years and older.